CM With MO CM Without MO
Fremanezumab Fremanezumab
Quarterly (n = 201) Monthly (n = 198) Placebo (n = 188) Quarterly (n = 174) Monthly(n = 177) Placebo(n = 183)
Age, mean (SD), y 44.6 (11.6) 44.8 (10.9) 45.0 (10.8) 39.0 (12.6) 36.2 (11.5) 37.7 (12.1)
Sex, female, n (%) 183 (91) 173 (87) 168 (89) 147 (84) 154 (87) 158 (86)
BMI, mean (SD), kg/m2 26.4 (5.3) 26.4 (5.0) 26.0 (5.0) 26.9 (5.5) 26.7 (5.3) 26.9 (5.1)
Disease history
 Years since initial migraine diagnosis, mean (SD) 21.0 (12.7) 22.8 (12.3) 23.2 (13.8) 18.3 (12.9) 17.1 (11.0) 16.7 (11.0)
 Current preventive medication use, n (%) 47 (23.4) 54 (27.3) 38 (20.2) 30 (17.2) 31 (17.5) 39 (21.3)
 Current use of triptans or ergots, n (%) 141 (70.1) 138 (69.7) 128 (68.1) 67 (38.5) 49 (27.7) 64 (35.0)
 Prior topiramate use, n (%) 65 (32.3) 72 (36.4) 77 (41.0) 41 (23.6) 43 (24.3) 40 (21.9)
 Prior onabotulinumtoxinA use, n (%) 38 (18.9) 34 (17.2) 32 (17.0) 28 (16.1) 16 (9.0) 17 (9.3)
Disease characteristics during the 28-day pretreatment period
 Number of headache days of at least moderate severity,b mean (SD) 15.5 (5.0) 14.9 (5.4) 14.8 (5.4) 10.5 (4.8) 10.5 (5.3) 11.7 (5.8)
 Number of migraine days,c mean (SD) 17.2 (4.6) 17.5 (4.9) 17.3 (5.0) 15.0 (4.9) 14.3 (5.0) 15.4 (5.1)
 Number of days of acute medication use, mean (SD) 18.1 (4.0) 18.4 (4.5) 18.2 (4.4) 7.4 (4.4) 7.1 (4.5) 7.7 (4.5)
 HIT-6 score, mean (SD) 64.5 (5.1) 65.3 (4.4) 63.8 (5.2) 64.0 (4.3) 63.9 (4.3) 64.3 (4.4)
 PHQ-9 score, mean (SD) 4.3 (5.5) 5.9 (6.7) 3.7 (5.7) 4.1 (5.6) 4.0 (5.6) 4.0 (5.6)
MSQoL domain scores
 RFR, mean (SD) 49.1 (18.9) 46.8 (19.7) 49.7 (20.5) 48.2 (18.3) 49.7 (18.7) 48.8 (19.2)
 RFP, mean (SD) 67.5 (21.1) 63.2 (23.5) 67.5 (22.9) 67.1 (20.4) 68.7 (20.6) 67.4 (21.7)
 EF, mean (SD) 58.4 (26.2) 54.3 (27.1) 58.0 (27.5) 55.8 (26.9) 60.4 (25.1) 57.7 (25.4)